Posters

Results of a Six-Month, Randomized, Controlled, Phase 3 Trial Comparing the Efficacy and Safety Of Probuphine™ to Placebo Implants, and Suboxone® for Opioid Addiction

Presented by Titan Pharmaceuticals at the 13th annual meeting of International Society of Addiction Medicine (ISAM), Oslo, Norway, September 2011.

Safety, Efficacy, and Pharmacokinetics of Probuphine®, a 6-Month Implantable Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Addiction

Presented by Titan Pharmaceuticals at American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, December 2009.

Long-term continuous delivery of the dopamine agonist lisuride with ProNeuraTM subcutaneous implants

Presented at the Society for Neuroscience 37th Annual Meeting in San Diego, California, November 2007.

Continuous dopaminergic stimulation reduces the risk of motor complications in animal models of Parkinson’s disease

Presented at the Society for Neuroscience Annual Meeting in New Orleans, Louisiana, November 2003.

• « Previous
• 1
• 2